71.19
price up icon0.69%   +0.515
 
loading
Gilead Sciences Inc stock is currently priced at $71.19, with a 24-hour trading volume of 793.68K. It has seen a +0.69% increased in the last 24 hours and a +8.34% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $70.80 pivot point. If it approaches the $72.05 resistance level, significant changes may occur.
Previous Close:
$70.67
Open:
$71
24h Volume:
793.68K
Market Cap:
$88.04B
Revenue:
$27.45B
Net Income/Loss:
$484.00M
P/E Ratio:
16.36
EPS:
4.35
Net Cash Flow:
$7.90B
1W Performance:
+10.72%
1M Performance:
+8.34%
6M Performance:
-10.67%
1Y Performance:
-8.15%
1D Range:
Value
$70.56
$71.45
52W Range:
Value
$62.07
$87.86

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Name
Gilead Sciences Inc
Name
Phone
(650) 574-3000
Name
Address
333 LAKESIDE DR, FOSTER CITY, CA
Name
Employee
18,000
Name
Twitter
@GileadSciences
Name
Next Earnings Date
2024-06-12
Name
Latest SEC Filings
Name
GILD's Discussions on Twitter

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-09-23 Initiated Deutsche Bank Hold
Sep-08-23 Upgrade BofA Securities Neutral → Buy
Sep-06-23 Initiated HSBC Securities Reduce
Jul-24-23 Reiterated Barclays Equal Weight
May-16-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-28-23 Resumed Piper Sandler Overweight
Jan-03-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-13-22 Resumed BofA Securities Neutral
Dec-09-22 Downgrade DZ Bank Buy → Hold
Oct-31-22 Upgrade Barclays Underweight → Equal Weight
Oct-28-22 Reiterated BMO Capital Markets Market Perform
Oct-28-22 Reiterated Cowen Outperform
Oct-28-22 Reiterated JP Morgan Overweight
Oct-28-22 Reiterated Jefferies Buy
Oct-28-22 Upgrade Piper Sandler Neutral → Overweight
Oct-28-22 Reiterated RBC Capital Mkts Outperform
Oct-28-22 Upgrade Truist Hold → Buy
Oct-28-22 Reiterated Wells Fargo Equal Weight
Oct-04-22 Upgrade JP Morgan Neutral → Overweight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
May-23-22 Initiated SVB Leerink Mkt Perform
Feb-28-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-02-22 Reiterated BMO Capital Markets Outperform
Feb-02-22 Reiterated BofA Securities Neutral
Feb-02-22 Reiterated RBC Capital Mkts Outperform
Feb-02-22 Reiterated Truist Hold
Feb-02-22 Reiterated Wells Fargo Equal Weight
Jan-28-22 Upgrade Argus Hold → Buy
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Upgrade BMO Capital Markets Market Perform → Outperform
Nov-19-21 Resumed Piper Sandler Neutral
Oct-20-21 Resumed Cowen Outperform
Jul-30-21 Reiterated BMO Capital Markets Market Perform
Jul-30-21 Reiterated RBC Capital Mkts Outperform
Apr-01-21 Upgrade Bernstein Mkt Perform → Outperform
Mar-30-21 Upgrade Redburn Neutral → Buy
Jan-19-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Nov-03-20 Resumed Morgan Stanley Equal-Weight
Oct-28-20 Initiated UBS Neutral
Sep-30-20 Resumed Jefferies Buy
Sep-15-20 Upgrade Maxim Group Hold → Buy
Jul-31-20 Reiterated Credit Suisse Neutral
Jul-31-20 Reiterated Morgan Stanley Equal-Weight
Jul-31-20 Reiterated Piper Sandler Overweight
Jul-31-20 Reiterated RBC Capital Mkts Outperform
Jul-31-20 Reiterated SunTrust Hold
Jul-31-20 Reiterated Wells Fargo Equal Weight
Jul-20-20 Upgrade Credit Suisse Underperform → Neutral
Jun-03-20 Upgrade SVB Leerink Mkt Perform → Outperform
May-26-20 Upgrade SunTrust Sell → Hold
May-01-20 Downgrade JP Morgan Overweight → Neutral
May-01-20 Downgrade Raymond James Outperform → Mkt Perform
May-01-20 Downgrade SunTrust Hold → Sell
Apr-27-20 Downgrade UBS Buy → Neutral
Apr-20-20 Downgrade BMO Capital Markets Outperform → Market Perform
Apr-20-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-17-20 Downgrade CFRA Hold → Sell
View All

Gilead Sciences Inc Stock (GILD) Financials Data

Gilead Sciences Inc (GILD) Revenue 2024

GILD reported a revenue (TTM) of $27.45 billion for the quarter ending March 31, 2024, a +1.50% rise year-over-year.
loading

Gilead Sciences Inc (GILD) Net Income 2024

GILD net income (TTM) was $484.00 million for the quarter ending March 31, 2024, a -91.33% decrease year-over-year.
loading

Gilead Sciences Inc (GILD) Cash Flow 2024

GILD recorded a free cash flow (TTM) of $7.90 billion for the quarter ending March 31, 2024, a -5.80% decrease year-over-year.
loading

Gilead Sciences Inc (GILD) Earnings per Share 2024

GILD earnings per share (TTM) was $0.36 for the quarter ending March 31, 2024, a -91.87% decline year-over-year.
loading

Gilead Sciences Inc Stock (GILD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Parsey Merdad
Chief Medical Officer
Apr 01 '24
Sale
72.96
2,000
145,920
96,304
Parsey Merdad
Chief Medical Officer
Feb 29 '24
Sale
72.74
8,230
598,624
92,706
Parsey Merdad
Chief Medical Officer
Feb 28 '24
Sale
73.18
2,000
146,360
100,936
GILEAD SCIENCES, INC.
10% Owner
Feb 12 '24
Buy
22.00
910,000
20,020,000
4,126,119
GILEAD SCIENCES, INC.
10% Owner
Jan 29 '24
Buy
21.00
15,238,095
319,999,995
30,061,124
Dickinson Andrew D
Chief Financial Officer
Jan 16 '24
Sale
85.78
5,000
428,900
101,534
Mercier Johanna
Chief Commercial Officer
Jan 09 '24
Sale
85.23
8,242
702,466
82,729
Dickinson Andrew D
Chief Financial Officer
Oct 17 '23
Sale
80.00
5,000
400,017
104,003
Parsey Merdad
Chief Medical Officer
Sep 12 '23
Sale
76.99
1,501
115,562
70,130
Dickinson Andrew D
Chief Financial Officer
Jul 20 '23
Sale
80.00
5,000
400,000
107,587
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
drug_manufacturers_general BMY
$42.02
price up icon 0.17%
drug_manufacturers_general SNY
$48.43
price up icon 2.46%
drug_manufacturers_general PFE
$28.12
price up icon 1.12%
$310.57
price up icon 0.78%
drug_manufacturers_general NVS
$107.45
price up icon 2.20%
Cap:     |  Volume (24h):